Brendon L Neuen1, Toshiaki Ohkuma1, Bruce Neal1, David R Matthews2, Dick de Zeeuw3, Kenneth W Mahaffey4, Greg Fulcher5, Qiang Li1, Meg Jardine1, Richard Oh6, Hiddo L Heerspink1,3, Vlado Perkovic7. 1. The George Institute for Global Health, University of New South Wales, Sydney, Australia. 2. Oxford Centre for Diabetes, Endocrinology and Metabolism, Harris Manchester College, University of Oxford, Oxford, UK. 3. University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 4. Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California. 5. Royal North Shore Hospital, Sydney, Australia; and. 6. Janssen Research & Development, LLC, Raritan, New Jersey. 7. The George Institute for Global Health, University of New South Wales, Sydney, Australia; vperkovic@georgeinstitute.org.au.
Abstract
BACKGROUND: If SGLT2 inhibitors protect the kidneys by reducing albuminuria as hypothesized, people with type 2 diabetes mellitus (T2DM) with higher albuminuria should benefit more. METHODS: We conducted a post-hoc analysis of data from the CANagliflozin cardioVascular Assessment Study (CANVAS) Program, which randomized 10,142 participants with T2DM and high cardiovascular risk tocanagliflozin or placebo. We assessed effects of canagliflozin on renal, cardiovascular, and safety outcomes by baseline albuminuria. The trial included 2266 participants (22.3%) with moderately increased albuminuria (urinary albumin/creatinine ratio [UACR] 30-300 mg/g) and 760 (7.5%) with severely increased albuminuria (UACR >300 mg/g) at baseline. RESULTS:Canagliflozin lowered albuminuria with greater proportional reductions in those with moderately and severely increased albuminuria (P heterogeneity<0.001). After week 13, canagliflozin slowed the annual loss of kidney function across albuminuria subgroups, with greater absolute reductions in participants with severely increased albuminuria (placebo-subtracted difference 3.01 ml/min per 1.73 m2 per year; P heterogeneity<0.001). Heterogeneity for the renal composite outcome of 40% reduction in eGFR, ESKD, or renal-related death was driven by lesser effects in participants with moderately increased albuminuria (P heterogeneity=0.03), but no effect modification was observed when albuminuria was fitted as a continuous variable (P heterogeneity=0.94). Cardiovascular and safety outcomes were mostly consistent across albuminuria levels including increased risks for amputation across albuminuria subgroups (P heterogeneity=0.66). Greater absolute risk reductions in the renal composite outcome were observed in participants with severely increased albuminuria (P heterogeneity=0.004). CONCLUSIONS: The proportional effects of canagliflozin on renal and cardiovascular outcomes are mostly consistent across patients with different levels of albuminuria, but absolute benefits are greatest among those with severely increased albuminuria.
RCT Entities:
BACKGROUND: If SGLT2 inhibitors protect the kidneys by reducing albuminuria as hypothesized, people with type 2 diabetes mellitus (T2DM) with higher albuminuria should benefit more. METHODS: We conducted a post-hoc analysis of data from the CANagliflozin cardioVascular Assessment Study (CANVAS) Program, which randomized 10,142 participants with T2DM and high cardiovascular risk to canagliflozin or placebo. We assessed effects of canagliflozin on renal, cardiovascular, and safety outcomes by baseline albuminuria. The trial included 2266 participants (22.3%) with moderately increased albuminuria (urinary albumin/creatinine ratio [UACR] 30-300 mg/g) and 760 (7.5%) with severely increased albuminuria (UACR >300 mg/g) at baseline. RESULTS:Canagliflozin lowered albuminuria with greater proportional reductions in those with moderately and severely increased albuminuria (P heterogeneity<0.001). After week 13, canagliflozin slowed the annual loss of kidney function across albuminuria subgroups, with greater absolute reductions in participants with severely increased albuminuria (placebo-subtracted difference 3.01 ml/min per 1.73 m2 per year; P heterogeneity<0.001). Heterogeneity for the renal composite outcome of 40% reduction in eGFR, ESKD, or renal-related death was driven by lesser effects in participants with moderately increased albuminuria (P heterogeneity=0.03), but no effect modification was observed when albuminuria was fitted as a continuous variable (P heterogeneity=0.94). Cardiovascular and safety outcomes were mostly consistent across albuminuria levels including increased risks for amputation across albuminuria subgroups (P heterogeneity=0.66). Greater absolute risk reductions in the renal composite outcome were observed in participants with severely increased albuminuria (P heterogeneity=0.004). CONCLUSIONS: The proportional effects of canagliflozin on renal and cardiovascular outcomes are mostly consistent across patients with different levels of albuminuria, but absolute benefits are greatest among those with severely increased albuminuria.
Authors: Xiaoxin X Wang; Jonathan Levi; Yuhuan Luo; Komuraiah Myakala; Michal Herman-Edelstein; Liru Qiu; Dong Wang; Yingqiong Peng; Almut Grenz; Scott Lucia; Evgenia Dobrinskikh; Vivette D D'Agati; Hermann Koepsell; Jeffrey B Kopp; Avi Z Rosenberg; Moshe Levi Journal: J Biol Chem Date: 2017-02-14 Impact factor: 5.157
Authors: Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Hiddo J L Heerspink; Tom Greene; Hocine Tighiouart; Ron T Gansevoort; Josef Coresh; Andrew L Simon; Tak Mao Chan; Fan Fan Hou; Julia B Lewis; Francesco Locatelli; Manuel Praga; Francesco Paolo Schena; Andrew S Levey; Lesley A Inker Journal: Lancet Diabetes Endocrinol Date: 2019-01-08 Impact factor: 32.069
Authors: Toshiharu Ninomiya; Vlado Perkovic; Bastiaan E de Galan; Sophia Zoungas; Avinesh Pillai; Meg Jardine; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Stephen Macmahon; John Chalmers Journal: J Am Soc Nephrol Date: 2009-05-14 Impact factor: 10.121
Authors: Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman Journal: N Engl J Med Date: 2016-06-14 Impact factor: 91.245
Authors: Simke W Waijer; Taha Sen; Clare Arnott; Bruce Neal; Jos G W Kosterink; Kenneth W Mahaffey; Chirag R Parikh; Dick de Zeeuw; Vlado Perkovic; Brendon L Neuen; Steven G Coca; Michael K Hansen; Ron T Gansevoort; Hiddo J L Heerspink Journal: Clin J Am Soc Nephrol Date: 2021-12-07 Impact factor: 8.237
Authors: Meg Jardine; Zien Zhou; Hiddo J Lambers Heerspink; Carinna Hockham; Qiang Li; Rajiv Agarwal; George L Bakris; Christopher P Cannon; David M Charytan; Tom Greene; Adeera Levin; Jing-Wei Li; Brendon L Neuen; Bruce Neal; Richard Oh; Megumi Oshima; Carol Pollock; David C Wheeler; Dick de Zeeuw; Hong Zhang; Bernard Zinman; Kenneth W Mahaffey; Vlado Perkovic Journal: Clin J Am Soc Nephrol Date: 2021-02-22 Impact factor: 8.237